Cello Therapeutics, Inc. (Cello) is a leading biotechnology company focused on developing novel nanoparticle delivery platforms for cancer treatment. Our nanoparticles are comprised of three main components—chemotherapy or immunomodulatory agents, biocompatible polymer, and natural cellular membrane. The drugs are loaded within the biodegradable polymer core, which is then coated with membrane derived from human cells. This cell membrane coating technology is a recent breakthrough in the field of nanomedicine. Our target is to treat all types of cancers with a single delivery platform. In vitro and in vivo studies suggest that these biomimetic nanoparticles significantly improve the performance of both chemotherapy and immunotherapy. One of our immunotherapy nanoparticle formulations has increased the cancer survival rate to 85-100% in a mouse cancer model in repeated in vivo studies.
Founded in 2016 in San Diego, CA, Cello has been committed to saving patients’ lives. We keep cancer patients in our hearts as we relentlessly develop and test new formulations that improve upon current cancer therapies. Our objective is to accelerate the process of delivering novel and effective medical treatments to cancer patients’ hands.
Cello is currently in pre-clinical testing and preparing to file applications to bring our first nanoparticle formulation into human clinical trials in the near future.